Practical guidance for successful global regulatory submissions:
Understanding FDA and PMDA data standards requirements
About this webinar
Data standards requirements for regulatory submissions are constantly evolving. The US Food and Drug Administration (FDA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) delineate these requirements through binding guidance documents, technical specifications and other reference documents collaboratively developed with industry consortiums.
Periodic updates introduce nuanced modifications to these standards and add to the challenge of navigating this dynamic regulatory landscape.
This webinar provides a comprehensive overview of the diverse requirements and guidance on interpreting them. The featured speakers share best practices and resources for attendees to discover further information and templates to facilitate the preparation of submission data packages that align with regulatory expectations. The featured speakers also conduct a practical analysis that compares FDA requirements with those of the PMDA in the context of data standardisation requirements within a submission package to provide attendees with useful insights.
Key topics:
- A practical analysis of the FDA and PMDA Data Standards Catalog and Technical Conformance Guide Details and Interpretation
- An introduction to the FDA guidance documents and technical specifications, and how to interpret them
- The importance of the Study Data Standardisation Plan and the Study Data Reviewer’s Guide
- Checking for compliance using the FDA Technical Rejection Criteria and the PMDA Study Validation Rules
- Considerations around the FDA Standard Safety Tables and Figures: Integrated Guide and the FDA MedDRA Queries (FMQs)
- Addressing conflicts between the CDISC Foundational Standards and the regulatory documents
- Considerations on developing a concise set of materials useful for both FDA and PMDA submissions
Register for this webinar today to obtain practical guidance for successful global regulatory submissions.
Who should attend
- Quality Assurance
- Project Management
- Regulatory Affairs
- Biostatistics
- Statistical Programming
- Data Management
- Data Standards
- Medical Writing
What you will learn
- A practical analysis of the FDA and PMDA Data Standards Catalog and Technical Conformance Guide Details and Interpretation
- An introduction to the FDA guidance documents and technical specifications and how to interpret them
- The importance of the Study Data Standardisation Plan and the Study Data Reviewer’s Guide
- Checking for compliance using the FDA Technical Rejection Criteria and the PMDA Study Validation Rules
- Considerations around the FDA Standard Safety Tables and Figures: Integrated Guide and the FDA MedDRA Queries (FMQs)
- Addressing conflicts between the CDISC Foundational Standards and the regulatory documents
- Considerations on developing a concise set of materials useful for both FDA and PMDA submissions
Featured Speakers
Kent Letourneau
Kent joined ICON in 1996, starting his career in biostatistics before moving on to roles in statistical programming leadership, regulatory submissions, and process and systems optimisation.
In 2015, Kent was appointed Head of ICON’s Global Data Standards team, overseeing the development, implementation, and governance of end-to-end standards, from data collection through analysis and reporting.
Sandra Minjoe
Sandra Minijoe joined ICON in February 2018. She has been in the biotech/pharma industry since 1993, with roles in standards, programming, statistics, data management and project management. Her education includes a BS in Mathematics and an MS in Statistics. She has prior experience at both sponsors (Genentech, Gilead, Xoma, Otsuka) and vendors (Accenture, Octagon).
Since joining the CDISC ADaM team in 2001, Sandra has contributed to many of the ADaM public documents and led several ADaM projects. She is a former ADaM Team Lead, represented ADaM in higher-level CDISC decisions, is a certified CDISC ADaM trainer, and regularly presents on ADaM topics at industry meetings.
Partner for this event
ICON
ICON is the world’s leading clinical research organisation, powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing a comprehensive suite of outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. Our outsourcing models can be adapted to suit small local trials to large global programs, including full service, standalone services, FSP and full asset development.
Related webinars
More from Icon.
Strategic approaches for early clinical trials in neurodegenerative diseases
Insights into first-in-human study design of oligonucleotides
When patients lead: Breaking barriers in ultra-rare disease drug development
ICH GCP E6(R3): Preparing for global implementation, assessing the impact, risk and requirements of the change
Becoming a sponsor of choice for high-performing sites
Riding the data wave: How pharma can navigate disruptions in open claims
Beyond the bench: The advantages of GMP over USP compounding in early phase development
Boosting clinical trial success in Alzheimer’s, Parkinson’s and other neurodegenerative diseases
Enhancing Clinical Trials in Obesity by Integrating Clinical Outcome Assessments and Digital Health Technologies
Introducing ICON Strategic Solutions FSP Services: How This Model Supports Sponsors in Korea
From Fragmented to Fluid: A Deep Dive into Claims Data Innovation
Get ready for a new wave of clinical trials in Schizophrenia: how Sites and Sponsors can avoid conceptual mistakes